Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Investor	Date	% Owned	Market Value	Shares	Chg. Shares	Chg. Shares %	% Portfolio
Capital Research and Management Company	2025-09-30	18.13523%	$10.93B	24.0M	-339.2K	-1.4%	0.4%
FMR LLC	2025-09-30	12.35069%	$7.44B	16.3M	928.6K	6.0%	0.3%
The Vanguard Group, Inc.	2025-09-30	10.268%	$6.19B	13.6M	268.3K	2.0%	0.1%
The Growth Fund of America	2025-09-30	7.52011%	$4.53B	9.9M	-246.0K	-2.4%	1.2%
BlackRock, Inc.	2025-09-30	7.48988%	$4.51B	9.9M	-73.6K	-0.7%	0.1%
Vanguard Index Funds - Vanguard Total Stock Market ETF
JP Morgan Asset Management
T. Rowe Price Group, Inc.
State Street Global Advisors, Inc.
Vanguard Index Funds - Vanguard Mid-Cap ETF
Baillie Gifford & Co.
New Perspective Fund
Geode Capital Management, LLC
AMCAP Fund
Dodge & Cox
Norges Bank Investment Management
Government Pension Fund Global
Orbis Investment Management Limited
Wellington Management Group LLP
American Funds Insurance Series - Growth Fund

Alnylam Pharmaceuticals, Inc.

Top Holders